Equities Analysts Offer Predictions for ALNY FY2026 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Equities research analysts at Leerink Partnrs cut their FY2026 earnings per share estimates for shares of Alnylam Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 2nd. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings of $0.07 per share for the year, down from their previous forecast of $0.12. The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03).

A number of other research firms have also weighed in on ALNY. Citigroup upped their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. StockNews.com cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their target price for the company from $280.00 to $328.00 in a report on Monday, March 24th. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Finally, Stifel Nicolaus raised their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $316.25.

Remove Ads

Alnylam Pharmaceuticals Stock Down 3.7 %

NASDAQ:ALNY traded down $8.63 during midday trading on Friday, reaching $224.32. The company had a trading volume of 1,026,529 shares, compared to its average volume of 848,252. The stock's fifty day simple moving average is $258.16 and its 200-day simple moving average is $259.83. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market capitalization of $29.18 billion, a price-to-earnings ratio of -103.37 and a beta of 0.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC grew its position in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 73 shares during the last quarter. Park Square Financial Group LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $28,000. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $33,000. OFI Invest Asset Management bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth $35,000. Finally, Colonial Trust Co SC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at about $35,000. Institutional investors own 92.97% of the company's stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares of the company's stock, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now directly owns 12,881 shares in the company, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.